Table 5.
Subgroup analysis for the response outcomes between hetrombopag monotherapy and combination regimens.
| Outcome | Baseline platelet count ≥ 50 × 109/L |
Baseline platelet count < 50 × 109/L |
||||
|---|---|---|---|---|---|---|
| Hetrombopag (n = 17) | Hetrombopag-rhTPO/rhIL-11 (n = 17) | P | Hetrombopag (n = 11) | Hetrombopag-rhTPO/rhIL-11 (n = 28) | P | |
| 14-d response | 15 (88.2) | 17 (100.0) | 0.485 | 7 (63.6) | 19 (67.9) | 0.968 |
| 21-d response | 16 (94.1) | 17 (100.0) | 0.943 | 9 (81.8) | 25 (89.3) | 0.609 |
| Chemotherapy dose reduction/treatment delay | 1 (5.9) | 0 (0) | 0.939 | 3 (27.3) | 12 (42.9) | 0.593 |
| Median time to response, days (95% CI) | 9.0 (7.8-10.2) | 5.0 (4.0-6.0) | 0.002 | 11.0 (4.6-17.4) | 12.0 (11.0-13.0) | 0.683 |
rhIL, recombinant human interleukin; rhTPO, recombinant human thrombopoietin.